|本期目录/Table of Contents|

[1]龚春水,许树根,胡玉清,等.舒洛地特联合坎地沙坦治疗糖尿病肾病4期患者临床疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2017,19(03):248-250.[doi:10.3969/j.issn.1672-271X.2017.03.006]
　GONG Chun-shui,XU Shu-gen,HU Yu-qing,et al.Efficacy observation of sulodexide and candesartan on 48 cases with diabetic nephropathyIV stage[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(03):248-250.[doi:10.3969/j.issn.1672-271X.2017.03.006]
点击复制

舒洛地特联合坎地沙坦治疗糖尿病肾病4期患者临床疗效观察()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第19卷
期数:
2017年03期
页码:
248-250
栏目:
出版日期:
2017-05-20

文章信息/Info

Title:
Efficacy observation of sulodexide and candesartan on 48 cases with diabetic nephropathyIV stage
作者:
龚春水; 许树根; 胡玉清; 卞小燕; 梁萌
作者单位：361003厦门，厦门大学附属成功医院肾内科
Author(s):
GONG Chun-shui;  XU Shu-gen;  HU Yu-qing; BIAN Xiao-yan; LIANG Meng
(Department of Nephrology, the Cheng-gong Affiliated Hospital of Xiamen University,Xiamen 361003,Fujian,China)
关键词:
舒洛地特; 坎地沙坦; 糖尿病肾病; 临床疗效
Keywords:
Sulodexide;  Candesartan;  Diabetic nephropathy;  Clinical effect
分类号:
R587.1；R587.24
DOI:
10.3969/j.issn.1672-271X.2017.03.006
文献标志码:
A
摘要:
目的 观察舒洛地特联合坎地沙坦治疗糖尿病肾病4期的临床疗效。方法 选取厦门大学附属成功医院于2014年8月至2015年10月间收治的48例糖尿病肾病4期患者作为研究对象，并将其随机分为舒洛地特组（14例）、坎地沙坦组（17例）及联合治疗组（17例），所有患者均随访12周，比较各组患者的临床有效率、24h尿蛋白、血浆白蛋白（ALB）、血肌酐（SCr）、总胆固醇（CHOL）、纤维蛋白原（FIB）。结果 治疗后3组患者尿蛋白水平较治疗前明显改善(P<0.05)，舒洛地特组尿蛋白量下降水平与坎地沙坦组比较差异无统计学意义(P>0.05)，联合治疗组尿蛋白量下降水平优于单独用药两组(P<0.05)，舒洛地特及联合治疗组治疗后FIB有显著下降(P<0.05)。各组患者ALB、SCr、CHOL在治疗前后比较差异无统计学意义(P>0.05)。结论 舒洛地特联合坎地沙坦能有效减少糖尿病肾病4期患者的尿蛋白水平，效果优于单一用药。
Abstract:
Objective To explore the clinical effect of sulodexide and candesartan on patients with diabetic nephropathy IV stage.Methods 48 patients with DN-IV stage were randomized divided into sulodexide group (14 cases), candesartan group (17 cases), candesartan and sulodexide group(17 cases) from 2014 August to 2015 October in the Cheng-gong Affiliated Hospital of Xiamen University. The follow-up was 12 weeks. After the treatment, the clinical efficiency, 24 h urinary protein, plasma albumin(ALB),serum creatinine (SCr), total cholesterol(CHOL), fibrinogen(FIB) were compared in three groups.Results Compared with those before treatment, the urinary protein of the three groups after treatment was significantly lower (P<0.05); while the 24 h urinary protein of sulodexide group and candesartan group was not significant different (P>0.05), and the urinary protein of the candesartan and sulodexide group were better than the other two groups (P<0.05); After the treatment the FIB of sulodexide group and candesartan and sulodexide group was significantly decreased (P<0.05); while there was no significant difference in ALB, SCr and CHOL of those groups before and after treatment (P> 0.05).Conclusion Sulodexide and candesartan get a satisfactory result on reducing the urinary protein level in the treatment of diabetic nephropathy IV stage.

参考文献/References:

[1]Gambaro G,Kinalska I,Oksa A,et al.Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients:the Di.N.A.S.randomized trial[J]. J Am Soc Nephrol，2002，13(6):1615-1625.
[2］王扬天，彭丽，叶小珍，等.舒洛地特治疗糖尿病肾病合并视网膜病变的临床疗效观察[J]. 医学研究生学报，2010，23（12）：1269-1272.
[3］中华中医药学会肾病分会.糖尿病肾病诊断、辨证分型及疗效评定标准（试行方案）[J]. 上海中医药杂志，2007，41（7）：7-8.
[4］Jha JC,Gray SP,Barit D,et al.Genetic targeting or pharmacologic inhibition of NADPH oxidase Nox4 provides renoprotection in long-term diabetic nephropathy[J]. J Am Soc Nephrol，2014，25(6):1237-1240.
[5］陈惠萍.糖尿病肾病患者肾小球滤过膜结构和功能及代谢指标的再认识[J]. 医学研究生学报，2010，23（8）：785-791.
[6］林可意，曾龙驿，舒冏，等．舒洛地特对糖尿病大鼠尿白蛋白排泄率及肾脏转化生长因子-β1表达的影响[J]．中华糖尿病杂志，2009，1(3) : 196-200.
[7］邵加庆.局部肾素-血管紧张素系统在2型糖尿病中的作用[J]. 医学研究生学报，2011，24（5）：449-452.
[8］Tiurenkov IN,Voronkov AV,Slietsans AA,et al. Effects of mexidol and sulodexide on the level of specific markers of endothelial dysfunction in animals with experimental diabetes mellitus [J]. Eksp Klin Farmakol，2012，75(5):14-16.
[9］Masola V, Onisto M,Zaza G,et al.A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition [J]. J Transl Med，2012，10（1）:213-216.
[10]万倩，张倩，薛耀明，等. 2型糖尿病肾病患者白蛋白尿的危险因素分析[J]. 实用医学杂志，2015，31（8）：1234-1237.
[11]Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J]. N Engl J Med，2001，34（5）: 870-878.
[12]Packham DK,Wolfe R,Reutens AT,et al.Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy[J]. J Am Soc Nephrol，2012，23(1):123-130.
[13]杨玲.D-二聚体、纤维蛋白原及抗凝血酶III联合检测对早期2型糖尿病肾病的诊断价值[J]. 东南国防医药，2015，17（4）：402-403.
[14]Tak E,Ridyard D,Kim JH,et al.CD73-Dependent generation of adenosine and endothelial adora2b signaling attenuate diabetic nephropathy [J]. J Am Soc Nephrol，2014，25(3):547-563.
[15]杨绪枫，汪年松.舒洛地特治疗糖尿病肾病作用机制的研究进展[J]. 中国中西医结合肾病杂志，2011，12（4）：365-367

相似文献/References:

[1]张 凯,胡文星,赵守城,等.依折麦布联合舒洛地特对高龄冠心病和糖尿病患者调脂、抗炎作用的临床观察[J].医学研究与战创伤救治(原医学研究生学报),2012,14(05):428.
　ZHANG Kai,HU Wen-xing,ZHAO Shou-cheng,et al.Clinical observation of ezetimibe co-administration with sulodexide adjusting lipids and anti-inflammation in elderly patients with CHD and DM[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(03):428.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2017-05-20